
Gilead has refined the pharmacokinetics of tenofovir disoproxil fumarate (TDF), an anchor drug in several single-tablet medications for HIV-1, to create tenofovir alafenamide (TAF). Phase II results indicate superior renal outcomes and equivalent clinical outcomes with TAF versus TDF.

























































































































































